A5054573839- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Cancer Treatment and Pharmacology
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Viral-associated cancers and disorders
- Eosinophilic Disorders and Syndromes
- Peptidase Inhibition and Analysis
- CNS Lymphoma Diagnosis and Treatment
- Venous Thromboembolism Diagnosis and Management
- Retinoids in leukemia and cellular processes
- Fungal Plant Pathogen Control
- Neutropenia and Cancer Infections
- Platelet Disorders and Treatments
- Immune Cell Function and Interaction
- Angiogenesis and VEGF in Cancer
- Atrial Fibrillation Management and Outcomes
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Fungal Infections and Studies
- HER2/EGFR in Cancer Research
Ewha Womans University
2016-2025
Ewha Womans University Medical Center
2008-2024
Baewha Women's University
2004-2024
St. Vincent's Hospital
2023
National University of Tucumán
2022
Technical University of Munich
2019
University Health Network
2018
Princess Margaret Cancer Centre
2018
University of Toronto
2018
University Medical Center of the Johannes Gutenberg University Mainz
2016
Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces direct and indirect antimyeloma activity has shown substantial efficacy as monotherapy in heavily pretreated patients with multiple myeloma, well combination bortezomib newly diagnosed myeloma.In this phase 3 trial, we randomly assigned 498 relapsed or refractory myeloma to receive (1.3 mg per square meter of body-surface area) dexamethasone (20 mg) alone (control group) daratumumab (16 kilogram body weight)...
Although much is known about the long-term outcome of patients undergoing left (distal) pancreatectomy for malignancy, comparatively little optimal management strategy residual transected pancreatic parenchyma and divided duct. Clinicopathological operative factors that may contribute to postoperative leak were evaluated.A retrospective review medical records 126 who underwent between June 1990 December 1999 at University Texas M. D. Anderson Cancer Center was performed.Indications included...
The aim of the Korean Imatinib Discontinuation Study was to identify predictors for safe and successful imatinib discontinuation. A total 90 patients with a follow-up ≥12 months were analyzed. After median 26.6 after discontinuation, 37 lost major molecular response. probability sustained response at 12 24 62.2% 58.5%, respectively. All who retreated therapy 16.9 months, all achieved again 3.9 resuming therapy. We observed newly developed or worsened musculoskeletal pain pruritus in 27 (30%)...
Primary intestinal non-Hodgkin lymphoma (NHL) is a heterogeneous disease with regard to anatomic and histologic distribution. Thus, analyses focusing on primary NHL large number of patients are warranted. We retrospectively analyzed 581 from 16 hospitals in Korea for this retrospective analysis. compared clinical features treatment outcomes according the site involvement subtypes. B-cell (n = 504, 86.7%) was more frequent than T-cell 77, 13.3%). Diffuse (DLBCL) most common subtype 386,...
The objective of this study was to identify prognostic factors for survival in patients with primary diffuse large B-cell lymphoma (DLBCL) the adrenal gland. Thirty one diagnosed DLBCL from 14 Korean institutions and treated R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine prednisone) were analyzed. Complete remission (CR) overall response rate after chemotherapy 54.8% 87.0%. 2-year estimates (OS) progression-free (PFS) 68.3% 51.1%. In achieving CR, significant prolongations OS...
<h2>Abstract</h2> Limited data exist on up-front autologous stem cell transplantation (ASCT) in extranodal natural killer/T lymphoma (ENKTL). Sixty-two patients (43 men and 19 women) with newly diagnosed ENKTL who underwent ASCT after primary therapy were identified. Poor-risk characteristics included advanced stage (50%), high-intermediate to high-risk International Prognostic Index (25.8%), group 3 4 of NK/T Cell Lymphoma (NKPI, 67.7%). Pretransplant responses complete remission 61.3%...
The present study aimed to directly compare the efficacy and safety of azacitidine decitabine in patients with myelodysplastic syndromes (MDS). We compared overall response rate (ORR) (complete responses, partial marrow complete haematological improvements), survival (OS), event-free (EFS), time leukaemic transformation, adverse outcomes between decitabine. To minimize effects treatment selection bias this observational study, adjustments were made using propensity-score matching method....
In stage I/II natural killer (NK)/T-cell lymphoma, concurrent chemoradiotherapy (CCRT) had previously been shown to result in superior outcome compared with anthracycline-containing regimens, which have since considered ineffective. The role of CCRT comparison approaches employing nonanthracycline-containing chemotherapy (CT) and sequential radiotherapy (RT) such patients remains be defined.Three hundred three untreated (207 men, 96 women; median age: 51, 18-86 years) NK/T-cell lymphoma who...
Abstract Purpose: Radotinib is a second-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) approved in Korea for chronic phase myeloid leukemia (CML-CP) patients newly diagnosed or with insufficient response to other TKIs. This study was conducted evaluate the efficacy and safety of radotinib as first-line therapy CML-CP. Experimental Design: multinational, open-label assigned (1:1:1) one two twice-daily doses, imatinib daily. The primary endpoint major molecular (MMR) by 12 months....
Peripheral T-cell lymphomas (PTCLs) are uncommon and their frequency is regionally heterogeneous. Several studies have been conducted to evaluate the clinical features treatment outcomes of this disease entity, but majority these were in limited areas, making it difficult comprehensively analyze relative features. Furthermore, no consensus for PTCLs has established. Therefore, we an Asia-specific study understand assess treatments Asian patients.We performed a multinational, multicenter,...
In 2010, we proposed the first Korean Guidelines for Prevention of Venous Thromboembolism (VTE).It was applicable to patients, by modifying contents second edition Japanese guidelines prevention VTE and 8th American College Chest Physicians (ACCP) evidence-based clinical practice guidelines.From 2007 2011, conducted a nationwide study regarding incidence after major surgery using Health Insurance Review Assessment Service (HIRA) database.In addition, have considered 9th ACCP Evidenced-Based...
Abstract The epithelial cells that form a barrier lining the lung airway are key regulators of neutrophil trafficking into lumen in variety inflammatory diseases. Although lipid mediator leukotriene B4 (LTB4) is known to be principal chemoattractant for recruiting neutrophils inflamed sites across epithelium, precise signaling mechanism involved remains largely unknown. In present study, therefore, we investigated pathway through which LTB4 induces transepithelial migration neutrophils. We...
Although recent studies have suggested that cessation of imatinib (IM) in chronic myeloid leukemia patients can be associated with sustained response, further validation is needed to explore predictive factors. In a prospective, multicenter study, phase were eligible for IM therapy after more than 3 years if they had no detectable BCR-ABL1 transcript at least 2 years. A total 48 median age 47 (19-74 years) enrolled. Twenty received post-transplant relapse. After follow-up 15.8 months...
High-dose chemotherapy followed by autologous stem cell transplantation (HDT/ASCT) offers a rescue option for T lymphoma patients with poor prognosis. However, the effectiveness of HDT/ASCT in various peripheral subtypes, optimal transplant timing, and prognostic factors that predict better outcomes, have not been identified. We retrospectively investigated clinical outcomes 64 Korean lymphoma, unspecified (PTCL-U) between March 1995 February 2007. The median age at was 44 years (range:...
Abstract The revised International Staging System (R‐ISS) has recently been developed to improve the risk stratification of multiple myeloma (MM) patients over ISS. We assessed R‐ISS in MM who were treated with novel agents as a primary therapy and evaluated its discriminative power ability reclassify from A total 514 newly diagnosed including thalidomide, bortezomib, lenalidomide included this retrospective analysis. With median follow‐up duration 42.3 months (range, 40.5–44.1), overall...